Keywords
--
How to Cite
Iastrebner, M. (2020). ¿Cabe un tratamiento con ruxolitinib en el síndrome respiratorio agudo severo por COVID-19?. Journal of Hematology, 24(1), 101–103. Retrieved from https://www.revistahematologia.com.ar/index.php/Revista/article/view/287
Abstract
- -
References
1. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19) [Internet]. StatPearls. StatPearls Publishing; 2020 [cited 2020 Mar 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32150360
2. Johns Hopkins CR. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) by Johns Hopkins Coronavirus Resource Center [Internet]. 2020 [cited 2020 Mar 26]. Available from: https://coronavirus.jhu.edu/map.html
3. Monitor del Covid-19. Cifras, medidas y actualizaciones sobre coronavirus. Ministerio de Salud, Redacción, República Argentina. https://www.redaccion.com.ar/coronavirus-tablero-con-cifras-medidas-y-actualizaciones-en-tiempo-real/
4. Dennis McGonagle et al. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmunity Reviews p 1-7
https://www.ncbi.nlm.nih.gov/pubmed/32251717
5. Banerjee S et al. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs (2017) 77:521–546 DOI 10.1007/s40265-017-0701-9
https://www.ncbi.nlm.nih.gov/pubmed/28255960
6. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Cell Discovery Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073332/pdf/41421_2020_Article_153.pdf
7. Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, Von Bubnoff N. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. [cited 2020 Mar 26]; https://www.futuremedicine.com/doi/pdf/10.2217/imt-2017-0156
8. Albeituni S, Verbist KC, Tedrick PE, Tillman H, Picarsic J, Bassett R, et al. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. Blood [Internet]. 2019 Jul 11 [cited 2020 Mar 26];134(2):147–59. Available from: https://ashpublications.org/blood/article/134/2/147/260697/Mechanisms-of-action-of-ruxolitinib-in-murine
9. Zinter MS, Herminston ML. Calming the storm in HLH. Blood [Internet]. 2019 Jul 11 [cited 2020 Mar 26];134(2):103–4. Available from: https://ashpublications.org/blood/article-pdf/134/2/103/1553887/bloodbld2019001333c.pdf
10. Sin JH, Zangardi ML. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report. Hematol Oncol Stem Cell Ther. 2019 Sep 1;12(3):166–70. https://reader.elsevier.com/reader/sd/pii/S165838761830116X?token=A5F61E3EC545FCE2A974769770B4C89C51A6F709445D8025AF6368AD7835EBE1B0ED05F35920448FA67EA2B2D6290DCC
11. Slostad J, Hoversten P, Haddox CL, Cisak K, Paludo J, Tefferi A. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience. Vol. 93, American Journal of Hematology. Wiley-Liss Inc.; 2018. p. E47–9.
https://www.ncbi.nlm.nih.gov/pubmed/29134683
12. Fioranelli M, Roccia MG, Lotti T. Treatment of dermatomyositis with ruxolitinib. Dermatol Ther [Internet]. 2016 Jul 1 [cited 2020 Mar 26];29(4):285. Available from: http://doi.wiley.com/10.1111/dth.12308
13. Aeschlimann F, Frémond M-L, Duffy D, Rice GI, Charuel J-L, Bondet V, et al. A Child With Severe Juvenile dermatomyositis Treated With Ruxolitinib. Brain. 2018 Oct 15;141:1–5.
14. Hermans MAW, Schrijver B, van Holten-Neelen CCPA, Gerth van Wijk R, van Hagen PM, van Daele PLA, et al. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release. Clin Exp Allergy [Internet]. 2018 Nov 1 [cited 2020 Mar 26];48(11):1412–20. Available from: http://doi.wiley.com/10.1111/cea.13217
15. Jakafi (ruxolitinib) dosing, indications, interactions, adverse effects, and more [Internet]. [cited 2020 Mar 26]. Available from: https://reference.medscape.com/drug/jakafi-ruxolitinib-999703
16. Ternavasio-De La Vega HG, Castaño-Romero F, Ragozzino S, Sánchez González R, Vaquero-Herrero MP, Siller-Ruiz M et al. Coronavirus, ospedale di Livorno, primi esiti positivi in pazienti trattati con farmaco “anti-terapie intensive” | Città di Livorno [Internet]. [cited 2020 Apr 1]. Available from: http://www.comune.livorno.it/articolo/coronavirus-ospedale-livorno-primi-esiti-positivi-pazienti-trattati-farmaco-anti-terapie
17. https://clinicaltrials.gov/ct2/show/NCT04331665?term=ruxolitinib&cond=Covid&draw=2
18. Harrison CM, VannucciAN. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016 30 1701:1707 https://www.ncbi.nlm.nih.gov/pubmed/27211272
19. Massimo Gadina, et al. Janus kinases to jakinibs: from basic insights to clinical practice Rheumatology. 2019;58:14-16 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657570/
2. Johns Hopkins CR. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) by Johns Hopkins Coronavirus Resource Center [Internet]. 2020 [cited 2020 Mar 26]. Available from: https://coronavirus.jhu.edu/map.html
3. Monitor del Covid-19. Cifras, medidas y actualizaciones sobre coronavirus. Ministerio de Salud, Redacción, República Argentina. https://www.redaccion.com.ar/coronavirus-tablero-con-cifras-medidas-y-actualizaciones-en-tiempo-real/
4. Dennis McGonagle et al. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmunity Reviews p 1-7
https://www.ncbi.nlm.nih.gov/pubmed/32251717
5. Banerjee S et al. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs (2017) 77:521–546 DOI 10.1007/s40265-017-0701-9
https://www.ncbi.nlm.nih.gov/pubmed/28255960
6. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Cell Discovery Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073332/pdf/41421_2020_Article_153.pdf
7. Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, Von Bubnoff N. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. [cited 2020 Mar 26]; https://www.futuremedicine.com/doi/pdf/10.2217/imt-2017-0156
8. Albeituni S, Verbist KC, Tedrick PE, Tillman H, Picarsic J, Bassett R, et al. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. Blood [Internet]. 2019 Jul 11 [cited 2020 Mar 26];134(2):147–59. Available from: https://ashpublications.org/blood/article/134/2/147/260697/Mechanisms-of-action-of-ruxolitinib-in-murine
9. Zinter MS, Herminston ML. Calming the storm in HLH. Blood [Internet]. 2019 Jul 11 [cited 2020 Mar 26];134(2):103–4. Available from: https://ashpublications.org/blood/article-pdf/134/2/103/1553887/bloodbld2019001333c.pdf
10. Sin JH, Zangardi ML. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report. Hematol Oncol Stem Cell Ther. 2019 Sep 1;12(3):166–70. https://reader.elsevier.com/reader/sd/pii/S165838761830116X?token=A5F61E3EC545FCE2A974769770B4C89C51A6F709445D8025AF6368AD7835EBE1B0ED05F35920448FA67EA2B2D6290DCC
11. Slostad J, Hoversten P, Haddox CL, Cisak K, Paludo J, Tefferi A. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience. Vol. 93, American Journal of Hematology. Wiley-Liss Inc.; 2018. p. E47–9.
https://www.ncbi.nlm.nih.gov/pubmed/29134683
12. Fioranelli M, Roccia MG, Lotti T. Treatment of dermatomyositis with ruxolitinib. Dermatol Ther [Internet]. 2016 Jul 1 [cited 2020 Mar 26];29(4):285. Available from: http://doi.wiley.com/10.1111/dth.12308
13. Aeschlimann F, Frémond M-L, Duffy D, Rice GI, Charuel J-L, Bondet V, et al. A Child With Severe Juvenile dermatomyositis Treated With Ruxolitinib. Brain. 2018 Oct 15;141:1–5.
14. Hermans MAW, Schrijver B, van Holten-Neelen CCPA, Gerth van Wijk R, van Hagen PM, van Daele PLA, et al. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release. Clin Exp Allergy [Internet]. 2018 Nov 1 [cited 2020 Mar 26];48(11):1412–20. Available from: http://doi.wiley.com/10.1111/cea.13217
15. Jakafi (ruxolitinib) dosing, indications, interactions, adverse effects, and more [Internet]. [cited 2020 Mar 26]. Available from: https://reference.medscape.com/drug/jakafi-ruxolitinib-999703
16. Ternavasio-De La Vega HG, Castaño-Romero F, Ragozzino S, Sánchez González R, Vaquero-Herrero MP, Siller-Ruiz M et al. Coronavirus, ospedale di Livorno, primi esiti positivi in pazienti trattati con farmaco “anti-terapie intensive” | Città di Livorno [Internet]. [cited 2020 Apr 1]. Available from: http://www.comune.livorno.it/articolo/coronavirus-ospedale-livorno-primi-esiti-positivi-pazienti-trattati-farmaco-anti-terapie
17. https://clinicaltrials.gov/ct2/show/NCT04331665?term=ruxolitinib&cond=Covid&draw=2
18. Harrison CM, VannucciAN. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016 30 1701:1707 https://www.ncbi.nlm.nih.gov/pubmed/27211272
19. Massimo Gadina, et al. Janus kinases to jakinibs: from basic insights to clinical practice Rheumatology. 2019;58:14-16 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657570/
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar
Downloads
Download data is not yet available.